An eighteen serum cytokine signature for discriminating Glioma from normal healthy individuals

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Nijaguna, Mamatha B ^a   Patil, Vikas ^a   Hegde, Alangar S ^b   Chandramouli, Bangalore A ^c   Arivazhagan, Arimappamagan ^c   Santosh, Vani ^c   Somasundaram, Kumaravel ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b SRI SATHYA SAI INSTITUTE OF HIGHER MEDICAL SCIENCES   (India)

^c NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; JANUS KINASE; LEUKEMIA INHIBITORY FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NERVE GROWTH FACTOR BETA SUBUNIT; STAT PROTEIN; STEM CELL FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GLIOBLASTOMA; HUMAN; MINIMALLY INVASIVE PROCEDURE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; ADULT; ASTROCYTOMA; BLOOD; BRAIN; BRAIN NEOPLASMS; GLIOMA; MIDDLE AGED; PATHOLOGY; SUPPORT VECTOR MACHINE; YOUNG ADULT;

ADULT; ASTROCYTOMA; BIOMARKERS, TUMOR; BRAIN; BRAIN NEOPLASMS; CYTOKINES; GLIOBLASTOMA; GLIOMA; HUMANS; MIDDLE AGED; SUPPORT VECTOR MACHINE; YOUNG ADULT;

EID: 84943524918     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137524     Document Type: Article

References (71)

1. Holland EC (2000) Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 97: 6242-6244.
2. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359: 492-507. doi: 10.1056/NEJMra0708126
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466. doi: 10.1016/S1470-2045(09)70025-7
4. Chen SD, Hou PF, Lou L, Jin X, Wang TH, et al. (2014) The correlation between MR diffusion-weighted imaging and pathological grades on glioma. Eur Rev Med Pharmacol Sci 18: 1904-1909
5. Lee J, Choi SH, Kim JH, Sohn CH, Lee S, et al. (2014) Glioma grading using apparent diffusion coefficient map: application of histogram analysis based on automatic segmentation. NMR Biomed 27: 1046-1052. doi: 10.1002/nbm.3153
6. Sahin N, Melhem ER, Wang S, Krejza J, Poptani H, et al. (2013) Advanced MR imaging techniques in the evaluation of nonenhancing gliomas: perfusion-weighted imaging compared with proton magnetic resonance spectroscopy and tumor grade. Neuroradiol J 26: 531-541.
7. Tietze A, Mouridsen K, Lassen-Ramshad Y, Ostergaard L (2015) Perfusion MRI derived indices of microvascular shunting and flow control correlate with tumor grade and outcome in patients with cerebral glioma. PLoS One 10: e0123044. doi: 10.1371/journal.pone.0123044
8. Wang XC, Zhang H, Tan Y, Qin JB, Wu XF, et al. (2014) Combined value of susceptibility-weighted and perfusion-weighted imaging in assessing who grade for brain astrocytomas. J Magn Reson Imaging 39: 1569-1574.
9. Ding Y, Xing Z, Liu B, Lin X, Cao D (2014) Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastases using susceptibility-weighted imaging. Brain Behav 4: 841-849. doi: 10.1002/brb3.288
10. Liang R, Li M, Wang X, Luo J, Yang Y, et al. (2014) Role of rCBV values derived from dynamic susceptibility contrast-enhanced magnetic resonance imaging in differentiating CNS lymphoma from high grade glioma: a meta-Analysis. Int J Clin Exp Med 7: 5573-5577.
11. Arimappamagan A, Somasundaram K, Thennarasu K, Peddagangannagari S, Srinivasan H, et al. (2013) A fourteen gene GBM prognostic signature identifies association of immune response pathway and mesenchymal subtype with high risk group. PLoS One 8: e62042. doi: 10.1371/journal.pone. 0062042
12. Reddy SP, Britto R, Vinnakota K, Aparna H, Sreepathi HK, et al. (2008) Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis. Clin Cancer Res 14: 2978-2987. doi: 10.1158/1078-0432.CCR-07-4821
13. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, et al. (2010) A multigene predictor of outcome in glioblastoma. Neuro Oncol 12: 49-57. doi: 10.1093/neuonc/nop007
14. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522. doi: 10.1016/j.ccr.2010.03.017
15. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006) Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173.
16. Rao SA, Srinivasan S, Patric IR, Hegde AS, Chandramouli BA, et al. (2014) A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma. PLoS One 9: e85200. doi: 10.1371/journal.pone. 0085200
17. Shukla S, Pia Patric IR, Thinagararjan S, Srinivasan S, Mondal B, et al. (2013) A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-kappaB nexus. Cancer Res 73: 6563-6573. doi: 10.1158/0008-5472.CAN-13-0298
18. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110. doi: 10.1016/j.ccr.2009.12.020
19. Kumar DM, Thota B, Shinde SV, Prasanna KV, Hegde AS, et al. (2010) Proteomic identification of haptoglobin alpha2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. J Proteome Res 9: 5557-5567. doi: 10.1021/pr1001737
20. Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, et al. (2010) Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 19: 1409-1422. doi: 10.1158/1055-9965.EPI-09-1077
21. Somasundaram K, Nijaguna MB, Kumar DM (2009) Serum proteomics of glioma: methods and applications. Expert Rev Mol Diagn 9: 695-707. doi: 10.1586/erm.09.52
22. Yang I, Han SJ, Kaur G, Crane C, Parsa AT (2010) The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci 17: 6-10. doi: 10.1016/j.jocn.2009.05.006
23. Badie B, Schartner J (2001) Role of microglia in glioma biology. Microsc Res Tech 54: 106-113
24. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4: 11-22.
25. Hao C, Parney IF, Roa WH, Turner J, Petruk KC, et al. (2002) Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol 103: 171-178.
26. Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, et al. (2013) Cytokine patterns in brain tumour progression. Mediators Inflamm 2013: 979748. doi: 10.1155/2013/979748
27. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
28. Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567-6572.
29. Li H, Fan X, Houghton J (2007) Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 101: 805-815.
30. Sung SY, Hsieh CL, Wu D, Chung LW, Johnstone PA (2007) Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer 31: 36-100
31. Dinarello CA (2007) Historical insights into cytokines. Eur J Immunol 37 Suppl 1: S34-45
32. Iwami K, Natsume A, Wakabayashi T (2011) Cytokine networks in glioma. Neurosurg Rev 34: 253-263; discussion 263-254. doi: 10.1007/s10143-011-0320-y
33. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014: 149185. doi: 10.1155/2014/149185
34. Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14: e218-228. doi: 10.1016/S1470-2045(12)70582-X
35. Paradkar PH, Joshi JV, Mertia PN, Agashe SV, Vaidya RA (2014) Role of cytokines in genesis, progression and prognosis of cervical cancer. Asian Pac J Cancer Prev 15: 3851-3864.
36. Zhu VF, Yang J, Lebrun DG, Li M (2012) Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis. Cancer Lett 316: 139-150. doi: 10.1016/j.canlet.2011.11.001
37. Tanwar MK, Gilbert MR, Holland EC (2002) Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62: 4364-4368
38. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, et al. (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12: 5698-5704.
39. Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad KS, et al. (2008) Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem 54: 713-722. doi: 10.1373/clinchem.2007. 096792
40. Lin Y, Jiang T, Zhou K, Xu L, Chen B, et al. (2009) Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol 11: 468-476. doi: 10.1215/15228517-2008-114
41. Hishii M, Nitta T, Ishida H, Ebato M, Kurosu A, et al. (1995) Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 37: 1160-1166; discussion 1166-1167
42. Huettner C, Paulus W, RoggendorfW(1995) Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 146: 317-322
43. Huettner C, Czub S, Kerkau S, RoggendorfW, Tonn JC (1997) Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 17: 3217-3224
44. Wagner S, Czub S, Greif M, Vince GH, Suss N, et al. (1999) Microglial/macrophage expression of interleukin 10 in human glioblastomas. Int J Cancer 82: 12-16.
45. Lichtor T, Glick RP (2003) Cytokine immuno-gene therapy for treatment of brain tumors. J Neurooncol 65: 247-259.
46. Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, et al. (2009) TGF-beta increases gliomainitiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15: 315-327. doi: 10.1016/j.ccr.2009.02.011
47. Takahashi JA, Mori H, Fukumoto M, Igarashi K, Jaye M, et al. (1990) Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci U S A 87: 5710-5714
48. Stefanik DF, Rizkalla LR, Soi A, Goldblatt SA, RizkallaWM (1991) Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res 51: 5760-5765
49. Morrison RS, Gross JL, Herblin WF, Reilly TM, LaSala PA, et al. (1990) Basic fibroblast growth factorlike activity and receptors are expressed in a human glioma cell line. Cancer Res 50: 2524-2529
50. Rahaman SO, Vogelbaum MA, Haque SJ (2005) Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2. Cancer Res 65: 2956-2963.
51. Weber F, Asher A, Bucholz R, Berger M, Prados M, et al. (2003) Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64: 125-137.
52. Sloan AE, Dansey R, Zamorano L, Barger G, Hamm C, et al. (2000) Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-Activated lymphocytes. Neurosurg Focus 9: e9.
53. Nagai M, Arai T (1984) Clinical effect of interferon in malignant brain tumours. Neurosurg Rev 7: 55-64.
54. Nakagawa Y, Hirakawa K, Ueda S, Suzuki K, Fukuma S, et al. (1983) Local administration of interferon for malignant brain tumors. Cancer Treat Rep 67: 833-835.
55. Yoshida J, Kajita Y, Wakabayashi T, Sugita K (1994) Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir (Wien) 127: 55-59.
56. Knupfer MM, Knupfer H, Jendrossek V, Van Gool S, Wolff JE, et al. (2001) Interferon-gamma inhibits growth and migration of A172 human glioblastoma cells. Anticancer Res 21: 3989-3994
57. Knupfer MM, Poppenborg H, Van Gool S, Domula M, Wolff JE (1997) Interferon-gamma inhibits proliferation and adhesion of T98G human malignant glioma cells in vitro. Klin Padiatr 209: 271-274
58. Sidky YA, Borden EC (1987) Inhibition of angiogenesis by interferons: effects on tumor-And lymphocyte-induced vascular responses. Cancer Res 47: 5155-5161
59. Farkkila M, Jaaskelainen J, Kallio M, Blomstedt G, Raininko R, et al. (1994) Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 70: 138-141
60. George J, Banik NL, Ray SK (2009) Combination of hTERT knockdown and IFN-gamma treatment inhibited angiogenesis and tumor progression in glioblastoma. Clin Cancer Res 15: 7186-7195. doi: 10.1158/1078-0432.CCR-09-1425
61. Haque A, Banik NL, Ray SK (2007) Emerging role of combination of all-trans retinoic acid and interferon-gamma as chemoimmunotherapy in the management of human glioblastoma. Neurochem Res 32: 2203-2209.
62. Cui L, Fu J, Pang JC, Qiu ZK, Liu XM, et al. (2012) Overexpression of IL-7 enhances cisplatin resistance in glioma. Cancer Biol Ther 13: 496-503. doi: 10.4161/cbt.19592
63. Oelmann E, Kraemer A, Serve H, Reufi B, Oberberg D, et al. (1997) Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1. Int J Cancer 71: 1066-1076
64. Tada M, Diserens AC, Desbaillets I, Jaufeerally R, Hamou MF, et al. (1994) Production of interleukin-1 receptor antagonist by human glioblastoma cells in vitro and in vivo. J Neuroimmunol 50: 187-194
65. Shevtsov MA, Nikolaev BP, Yakovleva LY, Dobrodumov AV, Zhakhov AV, et al. (2015) Recombinant interleukin-1 receptor antagonist conjugated to superparamagnetic iron oxide nanoparticles for theranostic targeting of experimental glioblastoma. Neoplasia 17: 32-42. doi: 10.1016/j.neo.2014.11.001
66. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, et al. (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13: 4677-4685.
67. Kimura S, Yoshino A, Katayama Y, Watanabe T, Fukushima T (2002) Growth control of C6 glioma in vivo by nerve growth factor. J Neurooncol 59: 199-205.
68. Murray PJ (2007) The JAK-STAT signaling pathway: input and output integration. J Immunol 178: 2623-2629.
69. Heim MH (1999) The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res 19: 75-120.
70. Nicolas CS, Amici M, Bortolotto ZA, Doherty A, Csaba Z, et al. (2013) The role of JAK-STAT signaling within the CNS. JAKSTAT 2: e22925. doi: 10.4161/jkst.22925
71. Tu Y, Zhong Y, Fu J, Cao Y, Fu G, et al. (2011) Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas. Med Oncol 28: 15-23. doi: 10.1007/s12032-010-9435-1